The Lithuanian government has blocked investments planned by the Avia Solutions Group controlled by
Gediminas Ziemelis in Vilnius airport. The reason is his ties with Russia and Belarus, Delfi reports.
At the beginning of March, the head of the State Security Department (SSS) of Lithuania,
Darius Jauniskis, said that intelligence has serious doubts about the reliability of Avia Solutions Group: “We have repeatedly informed those who make decisions about the activities of this enterprise, and we have certain information that causes serious doubts about the reliability and performance of the company. I will not name it specifically since this is secret information, but everyone who makes decisions received this information,” he said presenting an annual assessment of threats to national security in the Seimas.
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Baricitinib is a rheumatoid arthritis drug that is being used for the treatment of Covid-19 positive in combination with Remdesivir. (Representative image/AFP)
HYDERABAD: Pharma player Natco Pharma Limited on Monday said it has received emergency use authorisation approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from the Central Drugs Standard Control Organization (CDSCO).
Natco said it will be seeking a compulsory license for the drug, which is sold under the brand name Olumiant by Eli Lilly & Co, based on emergency use in light of the grave and serious public health emergency across India due to the Covid-19 pandemic.
May 03, 2021
Baricitinib in combination with Remdesivir, is used for treatment of Covid positive patients.
Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets from Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib in combination with Remdesivir, is used for treatment of Covid-19 positive patients.
Hyderabad-based Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic.
The company is ready to launch the product this week, so as to make it available to suffering patients across India, the release added.
Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment
PTI
Hyderabad |
Updated on
American pharma major Merck along with Ridgeback Bio therapeutics has developed the drug
Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients.
American pharma major Merck along with Ridgeback Bio therapeutics has developed Molnupiravir(MK-4482).
According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, it said.